Cancer CARtography: Charting out a new approach to cancer immunotherapy

Immunotherapy

Volumn 6, Issue 6, 2014, Pages 675-678

  Patel, Jaina M ^a   Dale, Gordon A ^a   Vartabedian, Vincent F ^a   Dey, Paulami ^a   Selvaraj, Periasamy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD19; chimeric antigen receptor; cytokine release syndrome

Indexed keywords

INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; STEROID; TOCILIZUMAB; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL ACUTE LYMPHOBLASTIC LEUKEMIA; B CELL LEUKEMIA; CANCER IMMUNOTHERAPY; CHIMERIC ANTIGEN RECEPTOR T CELL IMMUNOTHERAPY; CYTOKINE RELEASE SYNDROME; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; CELL TRANSPLANTATION; FEMALE; IMMUNOLOGY; IMMUNOTHERAPY; LEUKEMIA, B-CELL; MALE; T LYMPHOCYTE;

CELL TRANSPLANTATION; FEMALE; HUMANS; IMMUNOTHERAPY; LEUKEMIA, B-CELL; MALE; T-LYMPHOCYTES;

EID: 84904639562     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.44     Document Type: Article

References (10)

1. Davila ML, Brentjens R, Wang X, Riviere I, Sadelain M. How do CARs work?: Early insights from recent clinical studies targeting CD19. Oncoimmunology 1(9), 1577-1583 (2012).
2. Brentjens RJ, Davila ML, Riviere I et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5(177), 177ra138 (2013).
3. Davila ML, Riviere I, Wang X et al. Effcacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci. Transl. Med. 6(224), 224ra225 (2014).
4. Brocker T, Karjalainen K. Signals through T cell receptor-zeta chain alone are insuffcient to prime resting T lymphocytes. J. Exp. Med. 181(5), 1653-1659 (1995).
5. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M. Cancer patient T cells genetically targeted to prostate-specifc membrane antigen specifcally lyse prostate cancer cells and release cytokines in response to prostate-specifc membrane antigen. Neoplasia 1(2), 123-127 (1999).
6. Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modifed T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822-1826 (2011).
7. Kochenderfer JN, Feldman SA, Zhao Y et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32(7), 689-702 (2009).
8. Thomas DA, Kantarjian H, Smith TL et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 86(7), 1216-1230 (1999).
9. John LB, Kershaw MH, Darcy PK. Blockade of PD-1 immunosuppression boosts CAR T-cell therapy. Oncoimmunology 2(10), e26286 (2013).
10. Fedorov VD, Themeli M, Saedelain M. PD-1-and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5(215), 215ra172 (2013).